In this study, researchers from Turkey determined the prevalence and clinical impact of transfusion-transmitted virus (TTV) DNA in patients with chronic liver diseases.
The team evaluated this in the Southeast Anatolia region where hepatitis B and C viral infections are endemic.
|Transfusion-transmitted virus DNA was found in 78% of patients with chronic liver disease.|
|Medical Principles and Practice|
The researchers enrolled 60 patients (19 males, 41 females), who were diagnosed with chronic liver disease by clinical, biochemical and histologic, in this study.
The chronic liver disease group included 11 patients with hepatitis B, 44 with hepatitis C, and 5 with chronic liver disease of unknown etiology.
The team collected serum samples both the patients with chronic liver diseases and 45 healthy volunteer blood donors.
They investigated the presence of TTV DNA using PCR.
In the chronic hepatitis C group, the team used a scoring system to grade inflammation and stage of fibrosis.
The researcher detected TTV DNA in 78% of patients with chronic liver disease, and 11% of volunteers in the control group.
In addition, 91% of patients with hepatitis B, 73% of those with hepatitis C, and 100% of those with cryptogenic liver disease were positive for TTV DNA.
Dr Cemil Savasa's team concluded, "TTV is highly prevalent in patients with chronic liver diseases in Southeast Anatolia, Turkey, but no pathogenic effect attributable to TTV infection was detected".